Skip main navigation
Close Drawer MenuOpen Drawer Menu
Books

The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Back to table of contents
No Access

Chapter 12.Paroxetine

Edited by:
https://doi.org/10.1176/appi.books.9781615371624.as12

Sections

History and Discovery | Structure–Activity Relations and Pharmacological Profile | Pharmacokinetics and Disposition | Pharmacogenomics | Mechanism of Action | Indications and Efficacy | Side Effects and Toxicology | Drug–Drug Interactions | Conclusion | References

Excerpt

Paroxetine (marketed as Paxil, Pexeva, and Brisdelle) is classified as one of the selective serotonin reuptake inhibitors (SSRIs) because of its potent inhibition of presynaptic serotonin (5-hydroxytryptamine [5-HT]) uptake. It is also a relatively potent norepinephrine reuptake inhibitor, particularly at higher dosages. Paroxetine has received U.S. Food and Drug Administration (FDA) approval for the treatment of depression, panic disorder, social anxiety disorder (social phobia), generalized anxiety disorder, obsessive-compulsive disorder (OCD), posttraumatic stress disorder (PTSD), premenstrual dysphoric disorder (PMDD), and vasomotor symptoms (hot flashes) associated with menopause (the latter in a low-dosage formulation marketed as Brisdelle). Paroxetine also has demonstrated efficacy in child and adolescent OCD and social anxiety disorder.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.
  • Institutional Login
  • Sign in via OpenAthens
  • Register for access

  • Please login/register if you wish to pair your device and check access availability.

    Not a subscriber?

    Subscribe Now / Learn More

    PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

    Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).